Pages with the most revisions

Jump to navigation Jump to search

Showing below up to 500 results in range #101 to #600.

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

  1. Radiofrequency ablation‏‎ (3 revisions)
  2. Activity median thermodynamic diameter‏‎ (3 revisions)
  3. Lifetime risk estimates‏‎ (3 revisions)
  4. Virtue ethics‏‎ (3 revisions)
  5. Growth fraction‏‎ (3 revisions)
  6. Iso-effect plots‏‎ (3 revisions)
  7. Voxel phantom‏‎ (3 revisions)
  8. Radiological Protection in Healthcare‏‎ (3 revisions - redirect page)
  9. Excretion rate (instantaneous)‏‎ (3 revisions)
  10. Extrathoracic airways‏‎ (3 revisions)
  11. Galactic cosmic radiation‏‎ (3 revisions)
  12. Growth hormone (somatotropin)‏‎ (3 revisions)
  13. ICRP Publication 103‏‎ (3 revisions)
  14. Isomers‏‎ (3 revisions)
  15. DNA damage signalling‏‎ (3 revisions)
  16. Organ dose equivalent‏‎ (3 revisions)
  17. Fairness‏‎ (3 revisions)
  18. Absorption‏‎ (3 revisions)
  19. Gamma ray‏‎ (3 revisions)
  20. Dose equivalent‏‎ (3 revisions)
  21. Field-size effect (Volume effect)‏‎ (3 revisions)
  22. Gastrointestinal syndrome‏‎ (3 revisions)
  23. Biomedical research volunteer‏‎ (3 revisions)
  24. Cardiomyopathy‏‎ (3 revisions)
  25. Dose limit‏‎ (3 revisions)
  26. Recovery‏‎ (3 revisions)
  27. Flexible tissues‏‎ (3 revisions)
  28. Guide to the System of Radiological Protection‏‎ (3 revisions)
  29. Autonomy‏‎ (3 revisions)
  30. Spread-out Bragg peak‏‎ (3 revisions)
  31. Constancy test‏‎ (3 revisions)
  32. Wisdom‏‎ (3 revisions)
  33. Dose‏‎ (3 revisions)
  34. Dose limits‏‎ (3 revisions)
  35. Fluence‏‎ (3 revisions)
  36. Target region‏‎ (3 revisions)
  37. DS02‏‎ (3 revisions)
  38. Fluoroscopically guided interventions‏‎ (3 revisions)
  39. Annual dose‏‎ (3 revisions)
  40. Contamination‏‎ (3 revisions)
  41. Dose of record (E)‏‎ (3 revisions)
  42. Accountability‏‎ (3 revisions)
  43. Half-life, physical‏‎ (3 revisions)
  44. Cell death‏‎ (3 revisions)
  45. Potential exposure‏‎ (3 revisions)
  46. Exponential survival curve‏‎ (3 revisions)
  47. Annual limit on intake‏‎ (3 revisions)
  48. Low Earth orbit‏‎ (3 revisions)
  49. X ray‏‎ (3 revisions)
  50. Dose per content function‏‎ (3 revisions)
  51. Equity‏‎ (3 revisions)
  52. Graded approach‏‎ (3 revisions)
  53. Rigidity threshold‏‎ (3 revisions)
  54. Unsealed source‏‎ (3 revisions)
  55. Xerostomia‏‎ (3 revisions)
  56. Fractionation‏‎ (3 revisions)
  57. Test‏‎ (3 revisions)
  58. Public exposure‏‎ (3 revisions)
  59. Active (red) bone marrow‏‎ (3 revisions)
  60. Granulocyte-macrophage colony-stimulating factor‏‎ (3 revisions)
  61. Interphase death‏‎ (3 revisions)
  62. Latent time/period or latency interval‏‎ (2 revisions)
  63. Class SR-2 gases‏‎ (2 revisions)
  64. Low level waste‏‎ (2 revisions)
  65. Committed equivalent dose‏‎ (2 revisions)
  66. Dichotomous‏‎ (2 revisions)
  67. Dose rate effectiveness factor‏‎ (2 revisions)
  68. Qualified expert‏‎ (2 revisions)
  69. Emergency plan‏‎ (2 revisions)
  70. Radioactive substance‏‎ (2 revisions)
  71. Ethics‏‎ (2 revisions)
  72. ALARA‏‎ (2 revisions)
  73. Reference biokinetic model‏‎ (2 revisions)
  74. Relocation‏‎ (2 revisions)
  75. Risk coefficient‏‎ (2 revisions)
  76. Hierarchical tissues‏‎ (2 revisions)
  77. Area monitoring‏‎ (2 revisions)
  78. Individual monitoring‏‎ (2 revisions)
  79. Benthic‏‎ (2 revisions)
  80. Source term‏‎ (2 revisions)
  81. Bronchial region‏‎ (2 revisions)
  82. Substantial radiation dose level‏‎ (2 revisions)
  83. Clearance‏‎ (2 revisions)
  84. Transfer rate‏‎ (2 revisions)
  85. Multi-detector computed tomography‏‎ (2 revisions)
  86. Deontological Ethics‏‎ (2 revisions)
  87. Differentiation‏‎ (2 revisions)
  88. Percutaneous coronary intervention‏‎ (2 revisions)
  89. Prevailing circumstances‏‎ (2 revisions)
  90. Radon Recommendations for Authorities‏‎ (2 revisions)
  91. Reference individual‏‎ (2 revisions)
  92. Activity‏‎ (2 revisions)
  93. Remedial action‏‎ (2 revisions)
  94. ICRPædia Guide to Dose Coefficients‏‎ (2 revisions)
  95. High level waste‏‎ (2 revisions)
  96. Intervention Level‏‎ (2 revisions)
  97. Clearance level‏‎ (2 revisions)
  98. Lymphatic system‏‎ (2 revisions)
  99. Transforming growth factor‏‎ (2 revisions)
  100. Pericarditis‏‎ (2 revisions)
  101. Dose constraint‏‎ (2 revisions)
  102. Principle of application of dose limits‏‎ (2 revisions)
  103. Early normal tissue responses‏‎ (2 revisions)
  104. Radioactivity‏‎ (2 revisions)
  105. Radon Recommendations for Workplaces‏‎ (2 revisions)
  106. Reference level‏‎ (2 revisions)
  107. Remediation‏‎ (2 revisions)
  108. Risk of Exposure to Radon‏‎ (2 revisions)
  109. Beta-minus decay‏‎ (2 revisions)
  110. South Atlantic anomaly‏‎ (2 revisions)
  111. Interventional procedure‏‎ (2 revisions)
  112. Lifetime risk‏‎ (2 revisions)
  113. Macrophage colony stimulating factor‏‎ (2 revisions)
  114. Multiplicative risk projection model‏‎ (2 revisions)
  115. Cumulative dose‏‎ (2 revisions)
  116. Dose conversion coefficient‏‎ (2 revisions)
  117. Edema‏‎ (2 revisions)
  118. Excess relative risk‏‎ (2 revisions)
  119. Exposure situation‏‎ (2 revisions)
  120. Repopulation‏‎ (2 revisions)
  121. Growth factor‏‎ (2 revisions)
  122. Alimentary tract transfer factor‏‎ (2 revisions)
  123. Routine monitoring‏‎ (2 revisions)
  124. ICRPædia Guide to Radon‏‎ (2 revisions)
  125. Beta-plus decay‏‎ (2 revisions)
  126. Special (non-routine) monitoring‏‎ (2 revisions)
  127. Calculating Doses from Intakes of Radionuclides‏‎ (2 revisions)
  128. Clonogenic cells‏‎ (2 revisions)
  129. Threshold dose for tissue reactions‏‎ (2 revisions)
  130. Magnetosphere‏‎ (2 revisions)
  131. Curie‏‎ (2 revisions)
  132. Effect Dose 50‏‎ (2 revisions)
  133. Endogeneous excretion‏‎ (2 revisions)
  134. Radiographer‏‎ (2 revisions)
  135. Exposure to Radon at Home‏‎ (2 revisions)
  136. GATA binding protein 2‏‎ (2 revisions)
  137. Representative organism (non-human biota)‏‎ (2 revisions)
  138. ICRPædia Guide to the Basics of Ionising Radiation‏‎ (2 revisions)
  139. Hormones‏‎ (2 revisions)
  140. Authorization‏‎ (2 revisions)
  141. Limitation of dose‏‎ (2 revisions)
  142. Clonogenic survival‏‎ (2 revisions)
  143. Transmission detection system‏‎ (2 revisions)
  144. Multistage tumorigenesis‏‎ (2 revisions)
  145. Cytokines‏‎ (2 revisions)
  146. Non-sphericity parameter‏‎ (2 revisions)
  147. Pharynx‏‎ (2 revisions)
  148. Acute radiation syndrome‏‎ (2 revisions)
  149. Representative person‏‎ (2 revisions)
  150. Safety‏‎ (2 revisions)
  151. Hounsfield unit‏‎ (2 revisions)
  152. Authorized limit‏‎ (2 revisions)
  153. Specific effective energy‏‎ (2 revisions)
  154. Cardiac arrhythmias‏‎ (2 revisions)
  155. Lineal energy‏‎ (2 revisions)
  156. Thyroid blocking‏‎ (2 revisions)
  157. Transparency‏‎ (2 revisions)
  158. Waste disposal‏‎ (2 revisions)
  159. Non-targeted effects‏‎ (2 revisions)
  160. Disposal‏‎ (2 revisions)
  161. Dose criteria‏‎ (2 revisions)
  162. Procedural values‏‎ (2 revisions)
  163. Environmental exposure‏‎ (2 revisions)
  164. Exempt waste‏‎ (2 revisions)
  165. Adaptive response‏‎ (2 revisions)
  166. Reproductive integrity‏‎ (2 revisions)
  167. Alveolar-interstitial region‏‎ (2 revisions)
  168. Safety case‏‎ (2 revisions)
  169. Autoimmune disease‏‎ (2 revisions)
  170. Slow repair‏‎ (2 revisions)
  171. Isotropic geometry‏‎ (2 revisions)
  172. ICRP Publication 118‏‎ (2 revisions)
  173. Cardiac valve diseases‏‎ (2 revisions)
  174. Linear-non-threshold model‏‎ (2 revisions)
  175. Co-expertise‏‎ (2 revisions)
  176. Connective tissue‏‎ (2 revisions)
  177. Trapped particles‏‎ (2 revisions)
  178. DRL process‏‎ (2 revisions)
  179. Orphan source‏‎ (2 revisions)
  180. Planned exposure situation‏‎ (2 revisions)
  181. Progenitor cell‏‎ (2 revisions)
  182. Radiation belt‏‎ (2 revisions - redirect page)
  183. Environmental radiation protection‏‎ (2 revisions)
  184. Exemption level‏‎ (2 revisions)
  185. Reasonableness‏‎ (2 revisions)
  186. Residual dose‏‎ (2 revisions)
  187. Safety culture‏‎ (2 revisions)
  188. Solar cosmic radiation‏‎ (2 revisions)
  189. Inhalability‏‎ (2 revisions)
  190. Spontaneous fission‏‎ (2 revisions)
  191. Itinerant (radiation) worker‏‎ (2 revisions)
  192. Systemic model‏‎ (2 revisions)
  193. Linear-quadratic dose response model‏‎ (2 revisions)
  194. Time factor‏‎ (2 revisions)
  195. Consequential late effects‏‎ (2 revisions)
  196. Myocardial perfusion‏‎ (2 revisions)
  197. What is Radon?‏‎ (2 revisions)
  198. Platelet-derived growth factor‏‎ (2 revisions)
  199. Effective dose equivalent‏‎ (2 revisions)
  200. Radiation modifier‏‎ (2 revisions)
  201. Radiological protection principles‏‎ (2 revisions)
  202. Existing exposure situation‏‎ (2 revisions)
  203. Gastroschisis‏‎ (2 revisions)
  204. Respiratory protection‏‎ (2 revisions)
  205. Angiogenesis‏‎ (2 revisions)
  206. Scintigraphy‏‎ (2 revisions)
  207. Hyperbaric oxygen‏‎ (2 revisions)
  208. Solar cycle‏‎ (2 revisions)
  209. Inner bremsstrahlung‏‎ (2 revisions)
  210. Bioturbation‏‎ (2 revisions)
  211. Cardioverter-defibrillator‏‎ (2 revisions)
  212. Tachycardia‏‎ (2 revisions)
  213. Cohort study‏‎ (2 revisions)
  214. Tissue equivalent material‏‎ (2 revisions)
  215. Myocardial stress test‏‎ (2 revisions)
  216. DRL value‏‎ (2 revisions)
  217. Oversight‏‎ (2 revisions)
  218. Projected dose‏‎ (2 revisions)
  219. Epithelium‏‎ (2 revisions)
  220. Radionuclides of natural origin‏‎ (2 revisions)
  221. Recovery (cellular or tissue)‏‎ (2 revisions)
  222. Acceptance test‏‎ (2 revisions)
  223. Gastrulation‏‎ (2 revisions)
  224. Retrievability‏‎ (2 revisions)
  225. Habitual mouth breather‏‎ (2 revisions)
  226. Annihilation photons‏‎ (2 revisions)
  227. Immune system‏‎ (2 revisions)
  228. Hyperfractionation‏‎ (2 revisions)
  229. Institutional control‏‎ (2 revisions)
  230. Bone marrow‏‎ (2 revisions)
  231. Stakeholder‏‎ (2 revisions)
  232. Containment‏‎ (2 revisions)
  233. Worker‏‎ (2 revisions)
  234. Nuclear track detectors‏‎ (2 revisions)
  235. Dose-length product‏‎ (2 revisions)
  236. Radiation safety officer‏‎ (2 revisions)
  237. Equieffective dose‏‎ (2 revisions)
  238. Radioresponsiveness‏‎ (2 revisions)
  239. Expanded and aligned radiation field‏‎ (2 revisions)
  240. Recovery responder‏‎ (2 revisions)
  241. Adventitious‏‎ (2 revisions)
  242. Reversibility‏‎ (2 revisions)
  243. Habitual nose breather‏‎ (2 revisions)
  244. In vivo radiobioassay‏‎ (2 revisions)
  245. Hypertrophic cardiomyopathy‏‎ (2 revisions)
  246. Background dose (rate)‏‎ (2 revisions)
  247. Solar particle event‏‎ (2 revisions)
  248. Target tissue‏‎ (2 revisions)
  249. Measuring and Reducing Radon Levels in your Home‏‎ (2 revisions)
  250. Working level‏‎ (2 revisions)
  251. OLINDA/EXM‏‎ (2 revisions)
  252. Detriment‏‎ (2 revisions)
  253. Particle radiance‏‎ (2 revisions)
  254. Dose-rate effect‏‎ (2 revisions)
  255. Protection strategy‏‎ (2 revisions)
  256. Electron-capture decay‏‎ (2 revisions)
  257. Radiation source‏‎ (2 revisions)
  258. Radiosensitiser‏‎ (2 revisions)
  259. Fluoroscopically or computed tomography guided interventions‏‎ (2 revisions)
  260. Rehabilitation of living conditions‏‎ (2 revisions)
  261. Right to know‏‎ (2 revisions)
  262. Incidence‏‎ (2 revisions)
  263. Hypoplasia‏‎ (2 revisions)
  264. Backscatter detection system‏‎ (2 revisions)
  265. Solar wind‏‎ (2 revisions)
  266. Bradycardia‏‎ (2 revisions)
  267. Local DRL‏‎ (2 revisions)
  268. Tolerability‏‎ (2 revisions)
  269. Medical exposure‏‎ (2 revisions)
  270. Coronary heart disease‏‎ (2 revisions)
  271. Naturally occurring radioactive material‏‎ (2 revisions)
  272. Decay constant‏‎ (2 revisions)
  273. Working level month‏‎ (2 revisions)
  274. Dose of record Hp (10)‏‎ (2 revisions)
  275. Electrophysiology‏‎ (2 revisions)
  276. Radiosensitivity, cellular‏‎ (2 revisions)
  277. Accreditation‏‎ (2 revisions)
  278. Genomic integrity‏‎ (2 revisions)
  279. Rigidity‏‎ (2 revisions)
  280. Hazard‏‎ (2 revisions)
  281. Security‏‎ (2 revisions)
  282. Incident‏‎ (2 revisions)
  283. Intermediate level waste‏‎ (2 revisions)
  284. Bragg peak‏‎ (2 revisions)
  285. Stenosis‏‎ (2 revisions)
  286. Chronic exposure‏‎ (2 revisions)
  287. Telangiectasia‏‎ (2 revisions)
  288. Colony‏‎ (2 revisions)
  289. Member of the public‏‎ (2 revisions)
  290. Cosmic Radiation in Aviation‏‎ (2 revisions)
  291. Unattached fraction‏‎ (2 revisions)
  292. Necrosis‏‎ (2 revisions)
  293. Decommissioning‏‎ (2 revisions)
  294. Patient entrance reference point‏‎ (2 revisions)
  295. Dose-threshold‏‎ (2 revisions)
  296. Potential recoverability correction factor‏‎ (2 revisions)
  297. Protective action guide‏‎ (2 revisions)
  298. Radiation worker‏‎ (2 revisions)
  299. Fractional absorption in the gastrointestinal tract‏‎ (2 revisions)
  300. Action Level‏‎ (2 revisions)
  301. Health Surveillance‏‎ (2 revisions)
  302. Inclusiveness‏‎ (2 revisions)
  303. Basal cell‏‎ (2 revisions)
  304. Source-related‏‎ (2 revisions)
  305. Internal conversion electron‏‎ (2 revisions)
  306. Branching fraction‏‎ (2 revisions)
  307. LD 50/30‏‎ (2 revisions)
  308. Class SR-0 gases‏‎ (2 revisions)
  309. Track structure‏‎ (2 revisions)
  310. Mendelian diseases‏‎ (2 revisions)
  311. Neurological syndrome‏‎ (2 revisions)
  312. Decontamination‏‎ (2 revisions)
  313. Occupational exposure‏‎ (2 revisions)
  314. Diastasis‏‎ (2 revisions)
  315. Peak skin dose‏‎ (2 revisions)
  316. Dose per unit intake coefficient‏‎ (2 revisions)
  317. Emergency‏‎ (2 revisions)
  318. Radioactive dispersion device‏‎ (2 revisions)
  319. Radon: Units of Measure‏‎ (2 revisions)
  320. Exposure, external or internal‏‎ (2 revisions)
  321. Reference air kerma‏‎ (2 revisions)
  322. Graft vs host disease‏‎ (2 revisions)
  323. Air-kerma, incident‏‎ (2 revisions)
  324. Heliosphere‏‎ (2 revisions)
  325. Self-help protection‏‎ (2 revisions)
  326. Individual-related‏‎ (2 revisions)
  327. Storage‏‎ (2 revisions)
  328. Class SR-1 gases‏‎ (2 revisions)
  329. Low dose rate‏‎ (2 revisions)
  330. Committed effective dose‏‎ (2 revisions)
  331. Transfer compartment‏‎ (2 revisions)
  332. Mitigation‏‎ (2 revisions)
  333. Cost-benefit analysis‏‎ (2 revisions)
  334. Upper reference levels‏‎ (2 revisions)
  335. Neurovascular syndrome‏‎ (2 revisions)
  336. Decontamination factor‏‎ (2 revisions)
  337. Pelagic‏‎ (2 revisions)
  338. Practical radiological protection culture‏‎ (2 revisions)
  339. Dose rate‏‎ (2 revisions)
  340. Emergency exposure situation‏‎ (2 revisions)
  341. Radioactive source‏‎ (2 revisions)
  342. Erythropoietin‏‎ (2 revisions)
  343. Exposure (in the context of inhalation)‏‎ (2 revisions)
  344. Fractionation and dose delivery patterns‏‎ (2 revisions)
  345. ICRP Task Groups on Radiological Protection in Healthcare‏‎ (2 revisions)
  346. Individual decontamination‏‎ (2 revisions)
  347. Broad beam therapy irradiation technique‏‎ (2 revisions)
  348. Subcutaneous tissue‏‎ (2 revisions)
  349. Sublethal damage repair‏‎ (1 revision)
  350. ICRP Publication 127‏‎ (1 revision)
  351. ICRP Publication 141‏‎ (1 revision)
  352. Transfer of risk‏‎ (1 revision)
  353. Molecular imaging‏‎ (1 revision)
  354. ICRP Publication 16‏‎ (1 revision)
  355. Noise‏‎ (1 revision)
  356. ICRP Publication 30‏‎ (1 revision)
  357. Dental and maxillofacial imaging‏‎ (1 revision)
  358. ΓH2AX foci‏‎ (1 revision)
  359. Operating management‏‎ (1 revision)
  360. ICRP Publication 37‏‎ (1 revision)
  361. Pencil beam‏‎ (1 revision)
  362. ICRP Publication 51‏‎ (1 revision)
  363. Practice‏‎ (1 revision)
  364. ICRP Publication 66‏‎ (1 revision)
  365. ICRP Publication 80‏‎ (1 revision)
  366. Active detection system‏‎ (1 revision)
  367. Severe deterministic injury‏‎ (1 revision)
  368. ICRP Publication 100‏‎ (1 revision)
  369. Intervention‏‎ (1 revision)
  370. ICRP Publication 112‏‎ (1 revision)
  371. Licensee‏‎ (1 revision)
  372. ICRP Publication 128‏‎ (1 revision)
  373. Thermodynamic diameter‏‎ (1 revision)
  374. Low linear energy transfer radiation‏‎ (1 revision)
  375. ICRP Publication 142‏‎ (1 revision)
  376. Compartment‏‎ (1 revision)
  377. ICRP Publication 17‏‎ (1 revision)
  378. Count median diameter‏‎ (1 revision)
  379. Nominal risk coefficient‏‎ (1 revision)
  380. ICRP Publication 30 (Index)‏‎ (1 revision)
  381. ICRP Publication 38‏‎ (1 revision)
  382. ICRP Publication 52‏‎ (1 revision)
  383. Dose commitment‏‎ (1 revision)
  384. ICRP Publication 67‏‎ (1 revision)
  385. Doubling dose‏‎ (1 revision)
  386. Quality control testing‏‎ (1 revision)
  387. ICRP Publication 81‏‎ (1 revision)
  388. Radioactive waste‏‎ (1 revision)
  389. Evacuation‏‎ (1 revision)
  390. Exposure index‏‎ (1 revision)
  391. AML/eto‏‎ (1 revision)
  392. Frequent flyer‏‎ (1 revision)
  393. Risk model‏‎ (1 revision)
  394. Attributable risk‏‎ (1 revision)
  395. Sheltering‏‎ (1 revision)
  396. Induced genomic instability‏‎ (1 revision)
  397. ICRP Publication 101‏‎ (1 revision)
  398. Best available techniques‏‎ (1 revision)
  399. ICRP Publication 113‏‎ (1 revision)
  400. Bronchiolar region‏‎ (1 revision)
  401. Superposition principle‏‎ (1 revision)
  402. Life Span Study‏‎ (1 revision)
  403. ICRP Publication 129‏‎ (1 revision)
  404. Thoracic airways‏‎ (1 revision)
  405. ICRP Publication 143‏‎ (1 revision)
  406. Compartment (environmental)‏‎ (1 revision)
  407. Multifactorial diseases‏‎ (1 revision)
  408. ICRP Publication 18‏‎ (1 revision)
  409. Cross section‏‎ (1 revision)
  410. Nominal value‏‎ (1 revision)
  411. ICRP Publication 30 (Part 1)‏‎ (1 revision)
  412. Deposition‏‎ (1 revision)
  413. ICRP Publication 39‏‎ (1 revision)
  414. Digital breast tomosynthesis‏‎ (1 revision)
  415. ICRP Publication 53‏‎ (1 revision)
  416. ICRP Publication 68‏‎ (1 revision)
  417. ICRP Publication 82‏‎ (1 revision)
  418. Excess absolute risk‏‎ (1 revision)
  419. Exposure pathway‏‎ (1 revision)
  420. Functional subunits‏‎ (1 revision)
  421. Activity median aerodynamic diameter‏‎ (1 revision)
  422. Ground-level enhancement‏‎ (1 revision)
  423. ICRPædia Guide to Radiological Protection in Healthcare‏‎ (1 revision - redirect page)
  424. Shielding‏‎ (1 revision)
  425. ICRP Publication 101a‏‎ (1 revision)
  426. ICRP Publication 114‏‎ (1 revision)
  427. Supervised area‏‎ (1 revision)
  428. ICRP Publication 13‏‎ (1 revision)
  429. Clinical audit‏‎ (1 revision)
  430. Thoron progeny‏‎ (1 revision)
  431. ICRP Publication 144‏‎ (1 revision)
  432. Transgenerational effect‏‎ (1 revision)
  433. ICRP Publication 19‏‎ (1 revision)
  434. Non-homologous end joining‏‎ (1 revision)
  435. ICRP Publication 30 (Part 2)‏‎ (1 revision)
  436. Optimisation of protection‏‎ (1 revision)
  437. ICRP Publication 4‏‎ (1 revision)
  438. ICRP Publication 54‏‎ (1 revision)
  439. ICRP Publication 69‏‎ (1 revision)
  440. Quasi-threshold dose‏‎ (1 revision)
  441. ICRP Publication 83‏‎ (1 revision)
  442. Radon progeny‏‎ (1 revision)
  443. Reference parameter value‏‎ (1 revision)
  444. Homologous recombination‏‎ (1 revision)
  445. Authorised discharge‏‎ (1 revision)
  446. ICRP Publication 101b‏‎ (1 revision)
  447. ICRP Publication 115‏‎ (1 revision)
  448. Surface contamination‏‎ (1 revision)
  449. ICRP Publication 130‏‎ (1 revision)
  450. ICRP Publication 145‏‎ (1 revision)
  451. Translocation‏‎ (1 revision)
  452. Multistage carcinogenesis model‏‎ (1 revision)
  453. ICRP Publication 2‏‎ (1 revision)
  454. ICRP Publication 30 (Part 3)‏‎ (1 revision)
  455. Derived consideration reference level‏‎ (1 revision)
  456. ICRP Publication 40‏‎ (1 revision)
  457. Phantom‏‎ (1 revision)
  458. ICRP Publication 55‏‎ (1 revision)
  459. Dose conversion convention‏‎ (1 revision)
  460. ICRP Publication 7‏‎ (1 revision)
  461. ICRP Publication 84‏‎ (1 revision)
  462. Exclusion‏‎ (1 revision)
  463. Ras‏‎ (1 revision)
  464. Reference phantom‏‎ (1 revision)
  465. Acute exposure‏‎ (1 revision)
  466. ICRP Publication 90‏‎ (1 revision)
  467. Allometry‏‎ (1 revision)
  468. Size-specific dose estimate‏‎ (1 revision)
  469. ICRP Publication 102‏‎ (1 revision)
  470. Specific absorbed fraction‏‎ (1 revision)
  471. ICRP Publication 116‏‎ (1 revision)
  472. ICRP Publication 131‏‎ (1 revision)
  473. Threshold level‏‎ (1 revision)
  474. ICRP Publication 146‏‎ (1 revision)
  475. Concentration ratio‏‎ (1 revision)
  476. ICRP Publication 20‏‎ (1 revision)
  477. ICRP Publication 30 (Part 4)‏‎ (1 revision)
  478. Derived investigation level‏‎ (1 revision)
  479. Organ at risk‏‎ (1 revision)
  480. ICRP Publication 41‏‎ (1 revision)
  481. Directional dose equivalent‏‎ (1 revision)
  482. ICRP Publication 56‏‎ (1 revision)
  483. Dose conversion factor‏‎ (1 revision)
  484. Principles of protection‏‎ (1 revision)
  485. ICRP Publication 70‏‎ (1 revision)
  486. Effect modifier‏‎ (1 revision)
  487. Radiation-induced second cancer‏‎ (1 revision)
  488. ICRP Publication 85‏‎ (1 revision)
  489. Endosteum‏‎ (1 revision)
  490. Rb‏‎ (1 revision)
  491. Reference value‏‎ (1 revision)
  492. ICRP Publication 91‏‎ (1 revision)
  493. Slice‏‎ (1 revision)
  494. Biological half-life‏‎ (1 revision)
  495. ICRP Publication 117‏‎ (1 revision)
  496. ICRP Publication 132‏‎ (1 revision)
  497. Clonogenic surviving fraction‏‎ (1 revision)
  498. Marrow cellularity‏‎ (1 revision)
  499. ICRP Publication 147‏‎ (1 revision)
  500. Cone beam computed tomography‏‎ (1 revision)

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://icrpaedia.org/Special:MostRevisions"